Intensive Blood Pressure Control May Delay Progression in Advanced CKD
Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.
Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and novel biologic agents.
The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.
Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators.
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Trimethoprim-sulfamethoxazole is mostly excreted through the kidneys, and it can cause hyperkalemia by reducing potassium excretion.
Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.
One study focused on patients with severe lupus nephritis, who are at greatest risk for kidney failure.